Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
Ultragenyx (RARE) is transitioning from a broad pipeline to a focused rare disease platform, entering a high-catalyst period with four approved products and multiple late-stage assets. Despite a recent Phase 3 failure and Q1 2026 net loss, RARE reaffirmed 2026 revenue guidance of $730–$760 million, supported by a scalable commercial base and cost controls. Key near-term catalysts include FDA reviews for DTX401 and UX111 (PDUFA dates in H2 2026) and pivotal Phase 3 Aspire results for GTX-102 in Angelman syndrome.
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rare disease families find roadmap to drug development at bootcamps
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
There's a New Rare-Earth Stock. Here's What Makes It Stand Out.
Tuesday, Rare Earth Americas priced its IPO at $19 per share.
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.84 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $1.57 per share a year ago.
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
